✳flâneur — a map of the web's best reading

Home - IAVI

iavi.org · 93 words · saved by 1 readers

We are a nonprofit scientific research organization that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. We take a full-circle approach to product development, from the grassroots level to the lab to legislative bodies. To translate scientific discoveries into affordable, globally accessible public health solutions. A world where all people have equitable access to innovative vaccines and therapeutics. HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million people acquiring HIV in 2022. Given the complexities of HIV, traditional approaches to vaccine development have so far failed to result in a vaccine that provides protection against HIV. However, a vaccine is still needed to bring a true end to the HIV pandemic. Source: UNAIDS IAVI scientists and our collaborators are developing next-generation HIV vaccines to address the challenges of HIV vaccine design. Together, we have pioneered promising new vaccination strategies an

Features Phase 2b clinical trial of promising TB vaccine candidate MTBVAC has reached full enrollment July 22, 2026 IAVI and Biofabri are proud to announce that the Phase 2b clinical trial of tuberculosis (TB) vaccine candidate MTBVAC reached full enrollment on July 16, 2026. This trial, known as IMAGINE (Investigation of MTBVAC toward Accelerating Global Immunization for a Neglected Epidemic), has successfully completed its target of 5,500 participants enrolled across 16 clinical research centers in South Africa, Kenya, and Tanzania. The IMAGINE trial is designed to access safety and efficacy

Explore this link on the map →

related reading